New blood pressure drug takes on amlodipine in overweight patients
NCT ID NCT07241338
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a newer blood pressure drug, sacubitril/allisartan, to the standard drug amlodipine in 104 overweight or obese adults with high blood pressure. Participants will take one of the two drugs for 8 weeks, with dose adjustments if needed. The main goal is to see which drug lowers systolic blood pressure more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacubitril/allisartan (a blood pressure drug) and amlodipine (a standard blood pressure drug)
What this could lead to
If it works, this could show that sacubitril/allisartan is a better option for controlling blood pressure in people who are overweight or obese.
What could go wrong
This is a small, early-phase trial with only 104 participants and an 8-week duration, so results may not apply to everyone. It is also open-label, meaning both doctors and patients know which drug is given, which can bias results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••